Chemotherapy and HER2 targeted agents can improve survival significantly in metastatic breast
cancer. Chemotherapy however is associated with significant side-effects and can impact on
Quality of Life and functionality in older patients.
The investigators aim to establish HER2 targeted regimens with minimal toxicity in order to
delay or even avoid the use of classical chemotherapy because of competing risks of death in
this frail/elderly patient group.